{"disease":{"id":"hemophilia-a-or-b","name":"Hemophilia A or B","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":0},"drugs":{"marketed":[{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"concizumab","indication_name":"hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."},{"drug_id":"concizumab","indication_name":"hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."}],"pipeline":[{"drug_id":"marstacimab","indication_name":"Hemophilia A or B","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Marstacimab","generic_name":"marstacimab","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"For patients aged 12 years or older and weighing at least 35 kg, marstacimab is administered subcuta","quality_score":0,"revenue":null,"mechanism":"Marstacimab blocks a protein that normally prevents blood clotting, allowing patients with hemophilia to form clots more easily."}],"offLabel":[],"totalMarketed":4,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06820515","title":"ATHNdataset Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200000,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT06727669","title":"Longitudinal Cohort of Thrombosis and Hemostasis Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07205523","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Yigeng Cao,MD,PhD","has_results":false},{"nct_id":"NCT06938542","title":"Palliative Care Needs of Children With Rare Diseases and Their Families","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":480,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT03619863","title":"ATHN 7: Hemophilia Natural History Study","phase":"","overall_status":"COMPLETED","enrollment_count":395,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT03818529","title":"ATHN 8: Previously Untreated Patients (PUPs) Matter Study","phase":"","overall_status":"COMPLETED","enrollment_count":237,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT06569108","title":"Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":125,"lead_sponsor_name":"Suzhou Alphamab Co., Ltd.","has_results":false},{"nct_id":"NCT04647227","title":"SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT06312475","title":"Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":53,"lead_sponsor_name":"Suzhou Alphamab Co., Ltd.","has_results":false},{"nct_id":"NCT00851721","title":"Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT07161687","title":"A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03935334","title":"Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"AryoGen Pharmed Co.","has_results":false},{"nct_id":"NCT02764489","title":"FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT04272554","title":"AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)","phase":"","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Spur Therapeutics","has_results":false},{"nct_id":"NCT02919800","title":"A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"OPKO Health, Inc.","has_results":false},{"nct_id":"NCT02974855","title":"PF-06741086 Multiple Dose Study in Severe Hemophilia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05651061","title":"A Phase I of SS109 in Hemophilia A or and B With Inhibitors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Jiangsu Gensciences lnc.","has_results":false},{"nct_id":"NCT02484638","title":"Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT02448680","title":"A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Laboratoire français de Fractionnement et de Biotechnologies","has_results":true},{"nct_id":"NCT06010953","title":"SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Jiangsu Gensciences lnc.","has_results":false},{"nct_id":"NCT04768699","title":"Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT03363321","title":"PF-06741086 Long-term Treatment in Severe Hemophilia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04489537","title":"Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"Catalyst Biosciences","has_results":false},{"nct_id":"NCT06155955","title":"Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Chulalongkorn University","has_results":false},{"nct_id":"NCT06568302","title":"The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"ApcinteX Ltd","has_results":false},{"nct_id":"NCT04789954","title":"Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"AryoGen Pharmed Co.","has_results":false},{"nct_id":"NCT04072237","title":"Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Catalyst Biosciences","has_results":true},{"nct_id":"NCT03407651","title":"Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Catalyst Biosciences","has_results":true},{"nct_id":"NCT03520712","title":"Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":true}],"total":32},"guidelines":[],"source":"Drug Landscape verified database"}